American Century Companies Inc. Has $36.76 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

American Century Companies Inc. trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 46.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 141,041 shares of the medical research company’s stock after selling 121,667 shares during the period. American Century Companies Inc.’s holdings in Amgen were worth $36,761,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. DRW Securities LLC bought a new stake in shares of Amgen during the 3rd quarter worth about $244,000. Loomis Sayles & Co. L P lifted its position in Amgen by 6.6% during the third quarter. Loomis Sayles & Co. L P now owns 854 shares of the medical research company’s stock worth $275,000 after acquiring an additional 53 shares during the last quarter. Qsemble Capital Management LP bought a new stake in shares of Amgen during the third quarter worth approximately $230,000. Quantbot Technologies LP acquired a new position in shares of Amgen in the third quarter valued at approximately $150,000. Finally, Townsquare Capital LLC increased its stake in shares of Amgen by 3.1% during the third quarter. Townsquare Capital LLC now owns 28,794 shares of the medical research company’s stock worth $9,278,000 after purchasing an additional 855 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 0.0 %

NASDAQ AMGN opened at $305.77 on Friday. The company has a market cap of $164.26 billion, a price-to-earnings ratio of 40.50, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The business’s fifty day moving average is $300.39 and its 200 day moving average is $298.51.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.11%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

Insider Activity

In related news, EVP David M. Reese sold 25,225 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,341 shares of company stock valued at $20,644,335. Insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Piper Sandler upped their price objective on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Johnson Rice set a $294.00 price objective on shares of Amgen in a report on Wednesday, March 5th. UBS Group reaffirmed a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Finally, Citigroup reiterated a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $314.04.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.